CancerVax Corporation Announces FDA Approval Of IND For Novel Anti-Angiogenic Antibody D93
Published: Apr 03, 2006
CancerVax Corporation (NASDAQ: CNVX), a biotechnology company focused on the research, development and commercialization of biological products for the treatment of cancer, announced today that the United States Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application for D93, an investigational, humanized, monoclonal antibody with a novel anti-angiogenic and tumor inhibitory mechanism of action. Preclinical studies with D93 have demonstrated its ability to reduce angiogenesis and inhibit tumor growth in in vivo models of several types of cancer. CancerVax plans to initiate a Phase 1 clinical trial to evaluate the safety and tolerability of D93 in the treatment of patients with solid tumors later in 2006.